Affiliation:
1. Clinic of Anesthesia and Reanimation Afyonkarahisar State Hospital Afyonkarahisar Turkey
2. Department of Anatomy, Faculty of Medicine Afyonkarahisar Health Sciences University Afyonkarahisar Turkey
3. Department of Histology and Embryology, Faculty of Medicine Afyonkarahisar Health Sciences University Afyonkarahisar Turkey
4. Department of Anesthesia and Reanimation, Faculty of Medicine Yozgat Bozok University Yozgat Turkey
Abstract
AbstractSugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. The aim of this study is to investigate the teratogenic effects of sugammadex on neural tube and embryonic development in early chick embryos. In this study, 50 0‐day fertile specific non‐pathogenic (SPF) eggs were used. Fifty eggs were divided into 5 different groups, each consisting of 10 pieces. While no substance was given to the control group at the 28th hour of the study, 4 different doses of sugammadex were administered to the experimental groups, respectively 2, 4, 8, 16 mg/kg. Cranio‐caudal lengths of embryos, somite numbers, average number of argyrophilic nucleolar regulatory regions (AgNOR) per nucleus, total AgNOR area/total nuclear area (TAA/NA) ratios, Caspase‐3 H‐Score results, and presence of neural tube defect were compared among the groups. While the mean cranio‐caudal lengths, somite counts, TAA/NA ratios and AgNOR counts of the embryos were found to be statistically significantly lower than the control group, Caspase‐3 H‐Score mean results were found to be significantly higher (p < .05). In addition, it was observed that there was an increase in neural tube patency and developmental delay. As a result, sugammadex crossing the placenta was revealed to increase the release of proapopitotic molecules and disrupt the developmental stages of embryos. Thus, it was determined that sugammadex in increased developmental delay and incidence of neural tube defects in early chick embryos with increased dose dependent. Despite these results, the effects of sugammadex on fetal development in in vivo and in vitro environments should be studied with further studies.Research Highlights
Sugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. It has been observed that different doses of sugammadex increase the risk of neural tube defect development on chick embryos and slow the embryo development in a dose‐dependent manner.
Subject
Medical Laboratory Technology,Instrumentation,Histology,Anatomy
Reference39 articles.
1. Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium
2. Impact of Bisphenol A on neural tube development in 48‐hr chicken embryos
3. Australian Product Information Bridion® [Internet]. (2021).[cited 2021 Jun 6].https://secure.healthlinks.net.au/content/msd/pi.cfm?product=mkpbridi
4. Bridion® (sugammadex). (2015).Injection for intravenous use Initial U.S. Approval: 2015 [Internet]. [cited 2021 Jun 6].https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献